ENDRA Life Sciences Inc (NDRA) Stock Forecast & Price Target
ENDRA Life Sciences Inc · NASDAQ
$5.38+0.63 (+13.16%)
15-min delayed · Aug 26, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 1 firms covering ENDRA Life Sciences Inc, 1 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a strong buy consensus. Targets are tightly clustered, $25.00 to $25.00, so the covering firms are broadly aligned. The average target of $25.00 sits 365% above the current $5.38. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.84 next quarter toward $-3.04 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS1 ratings
Strong Buy
Strong Buy00%
Buy1100%
Hold00%
Sell00%
Strong Sell00%
Based on 1 analysts giving stock ratings to ENDRA Life Sciences Inc.
As of Aug, 1 of 1 firms rate NDRA a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
NDRA EPS & revenue forecast
EPS · NEXT QUARTER
$-0.84
Range $-0.84 – $-0.84 · 1 analysts · -62% YoY
Next period, 1 analysts expect ENDRA Life Sciences Inc to earn $-0.84 a share (range $-0.84 – $-0.84), versus $-2.23 a year earlier. Full-year consensus is $-3.54, growing to $-3.04 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 1 analysts
Revenue is expected to reach $0 (range $0 – $0). Full-year consensus is $0, rising to $200.0K next year.
Top analysts covering ENDRA Life Sciences Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on NDRA.
#1
Edward Woo
Ascendiant Capital · Rank #419
Buy
$25.00+365.1% to target
Overall win rate
25%
+ Follow
NDRA stock forecast FAQ
What is NDRA's average 12-month price target?+
The 1 analysts with a live target average $25.00 for ENDRA Life Sciences Inc over the next 12 months, ranging from a $25.00 high to a $25.00 low.
Is NDRA stock a Buy, Sell or Hold right now?+
The current consensus is Strong Buy. Of the 1 analyst ratings, 1 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
How many Wall Street analysts cover NDRA?+
1 analysts have an active rating on ENDRA Life Sciences Inc, and 1 firms carry a live 12-month price target.
Who is the most accurate analyst covering NDRA?+
Among analysts who currently cover NDRA, Edward Woo of Ascendiant Capital has the strongest overall Quantellect track record (Rank #419). Their current call is Buy with a $25.00 target.
What is ENDRA Life Sciences Inc's projected EPS for next quarter?+
The consensus estimate is $-0.84 per share (range $-0.84 – $-0.84) across 1 analysts. Full-year EPS is projected at $-3.54, rising to $-3.04 the following year.
How much revenue is ENDRA Life Sciences Inc expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $0, growing to $200.0K next year.
Have analysts been upgrading or downgrading NDRA lately?+
As of Aug, 1 of 1 firms rate NDRA a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their NDRA calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
